Patent: 9,592,247
✉ Email this page to a colleague
Summary for Patent: 9,592,247
| Title: | Method of reducing titers of antibodies specific for a therapeutic agent |
| Abstract: | The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods. |
| Inventor(s): | Kishnani; Priya S. (Durham, NC), Banugaria; Suhrad G. (Durham, NC), Koeberl; Dwight D. (Durham, NC), Prater; Sean N. (Durham, NC) |
| Assignee: | Duke University (Durham, NC) |
| Application Number: | 14/454,137 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,592,247
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-05-06 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-05-06 |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2030-05-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
